Immunotherapy,%20A2aR,%20PDR001,%20NIR178,%20NSCLC,%20solid%20tumors
Showing 26 - 50 of >10,000
Advanced Solid Tumors Trial in France, United States (IPH5401 and Durvalumab)
Terminated
- Advanced Solid Tumors
- IPH5401 and Durvalumab
-
Louisville, Kentucky
- +11 more
Jan 12, 2022
NSCLC, Tumor Metastasis Trial in Worldwide (LY3537982, Pembrolizumab, Placebo)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- LY3537982
- +5 more
-
Tucson, Arizona
- +217 more
Nov 1, 2023
Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)
Recruiting
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
-
Orange, California
- +13 more
Jan 31, 2023
Solid Tumor, Adult, NSCLC, Advanced Cancer Trial (Adagrasib, nab-Sirolimus)
Not yet recruiting
- Solid Tumor, Adult
- +4 more
- (no location specified)
Apr 24, 2023
Advanced Solid Tumor, Metastatic Solid Tumor, Lung Cancer Trial in Seoul, Incheon (WM-A1-3389, Pembrolizumab)
Not yet recruiting
- Advanced Solid Tumor
- +7 more
- WM-A1-3389
- Pembrolizumab
-
Seoul, Seocho-gu, Korea, Republic of
- +1 more
May 14, 2023
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Irvine, Chicago, Boston
Not yet recruiting
- Advanced Solid Tumor
- +4 more
- FPI-2053
- +2 more
-
Irvine, California
- +2 more
Nov 27, 2023
ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)
Active, not recruiting
- ALK-positive Advanced NSCLC
-
Orange, California
- +79 more
Nov 15, 2022
NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA Trial in France (Molecular monitoring by quantification of cell-free DNA)
Recruiting
- NSCLC
- +2 more
- Molecular monitoring by quantification of cell-free DNA
-
Besançon, France
- +7 more
Nov 18, 2022
Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jul 19, 2022
NSCLC, Urothelial Cancer Trial in Worldwide (Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in
Active, not recruiting
- Non-small Cell Lung Cancer
- Urothelial Cancer
- Avelumab 800 mg in combination with pemetrexed / carboplatin
- +3 more
-
Tucson, Arizona
- +45 more
Oct 13, 2022
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
Immune-related Adverse Event, Dietary Habits Trial (Food box containing 30 different plants)
Not yet recruiting
- Immune-related Adverse Event
- Dietary Habits
- Food box containing 30 different plants
- (no location specified)
Apr 14, 2023
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer Trial in Worldwide (INCB106385, INCMGA00012)
Recruiting
- Ovarian Cancer
- +10 more
-
West Hollywood, California
- +27 more
Jun 27, 2022
Metastatic Cancer Trial in Nanchang (High- and Low-dose radiotherapy)
Recruiting
- Metastatic Cancer
- High- and Low-dose radiotherapy
-
Nanchang, Jiangxi, China
- +1 more
Mar 6, 2023
Tumors by Site Trial in Worldwide (Relatlimab, Nivolumab, BMS-986213)
Active, not recruiting
- Neoplasms by Site
- Relatlimab
- +2 more
-
La Jolla, California
- +52 more
Feb 10, 2022
Carcinoma, Non-squamous Non-small-cell Lung Trial in Worldwide (Pembrolizumab, Pemetrexed, Carboplatin)
Active, not recruiting
- Carcinoma, Non-squamous Non-small-cell Lung
- Pembrolizumab
- +4 more
-
Birmingham, Alabama
- +177 more
Aug 22, 2022
Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- (no location specified)
Jun 16, 2023
Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Worldwide (NVL-520)
Recruiting
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
-
Orange, California
- +18 more
Oct 6, 2022
Patients With Advanced Solid Tumor (Excluding NSCLC, SCLC, and Mesothelioma) With Results From a Multi-gene Next-generation
Not yet recruiting
- Patients With Advanced Solid Tumor (Excluding NSCLC, SCLC, and Mesothelioma) With Results From a Multi-gene Next-generation Sequencing (NGS) Panel (>30 Genes)
- Minimal documentation
- Extended documentation
-
Mannheim, Baden-Württemberg, Germany
- +1 more
Jan 18, 2023
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)
Recruiting
- Triple Negative Breast Cancer
- +14 more
- LYL797
-
Scottsdale, Arizona
- +10 more
Jan 30, 2023
Advanced Solid Tumor, NSCLC Trial in Shanghai (XZB-0004)
Not yet recruiting
- Advanced Solid Tumor
- NSCLC
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Mar 5, 2023